For this reason, until a dedicated imaging technique with a specific tracer is available, such as Prostate-Specific Membrane Antigen (PSMA)-PET for prostate cancer, multimodality assessment staging is preferred to increase accuracy in those patients who are eligible for BSS [23]. This evidence concerns the gene FOLH1 and prostate carcinoma.